Releases
03/06/2021 14:27

While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy


NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, released its Q2 2021 Clinical Trials and the COVID-19 Vaccine Pulse Report, revealing an uphill battle for the United States as nearly a quarter of Americans remain hesitant around taking a COVID-19 vaccine.


The study, conducted online with the third-party research firm YouGov, uncovered not only the American publics sentiment around available COVID-19 vaccines, but also how their trust in pharmaceutical companies and understanding of clinical trials have changed following sentiments captured in Informa Pharma Intelligences 2020 Pulse Report when the first vaccines were still awaiting authorization for emergency use in the United States.


Vaccine Hesitancy Remains as U.S. Shifts Goal from Herd Immunity to Virus Manageability


Following the U.S. surpassing a huge milestone of 100 million COVID-19 vaccinations, achieving the next 100 million will be even more challenging as vaccine hesitancy remains among the American people.


Nearly a quarter (23%) of Americans say they would choose none of the three vaccines currently available from Pfizer-BioNTech, Moderna and Johnson & Johnson based on Phase III clinical trial results. However, over three-quarters (77%) say they would choose one of the vaccines available, with Pfizer-BioNTech the preference by far (with 42% selecting it). With the previous goal of herd immunity shifting toward virus manageability, President Bidens new aim of ensuring 70% of American adults have received at least one shot by July 4 could be attainable if current attitudes dont worsen.


Americans reported their top choice of COVID-19 vaccines based on Phase III clinical trial results:

  • Pfizer-BioNTech 42%
  • Moderna 25%
  • Johnson & Johnson 9%
  • None of these 23%

Understanding of Clinical Trials Up Among Americans


Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligences 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States.1


In fact, the percentage of Americans saying theyd be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). Furthermore, the number of Americans saying theyd be more likely to participate in a clinical trial doubled from 7% in 2020 to 13% in 2021. This may show that Americans are far more versed on vaccine clinical trial data due to the U.S. government and vaccine makers communicating this information more effectively since fall 2020.


Americans report additional attitudes toward COVID-19 vaccines, pharmaceutical companies and clinical trials, revealing further drops in negative perception:

  • 18% dont trust how quickly the COVID-19 vaccine clinical trials are moving (down from 35% in 2020)
  • 16% dont think pharma companies have consumers best interests in mind during clinical trials for the COVID-19 vaccine (down from 23% in 2020)

The Future of COVID-19 Vaccine Development


As pharma looks to the future of vaccine development, Americans report the following clinical trial factors as critical for them to be more likely to take a vaccine:

  • More than one in five (22%) Americans would be more likely to take a COVID-19 vaccine if the clinical trials showed sufficient results of working against new variants
  • Over a quarter (28%) of Americans with children under 18 would be more likely to have their child take a COVID-19 vaccine if they knew pediatric clinical trials showed sufficient safety and efficacy
  • More than one in seven (13%) Americans would be more likely to take a COVID-19 vaccine if they knew the clinical trials were demographically diverse

The U.S. is heading toward long-term management of COVID-19, but vaccine hesitancy is still a significant threat in terms of full mitigation, said Karen Currie, MPH, Executive Director of Citeline at Informa Pharma Intelligence. Transparency, consistency and accuracy in communication around the vaccines will be essential to turning the tide on the spread of the virus. This report reveals the importance of public health experts tailoring their outreach to specific groups, especially those that are reporting higher rates of hesitancy, with detailed information on safety and efficacy from clinical trials. Trust must continue to be built among the American people, government and pharmaceutical companies as we work together to save lives, effectively corner the virus and emerge from this pandemic.


Research Methodology
All figures, unless otherwise stated, are from YouGov Plc. Total sample size was 1327 adults. Fieldwork was undertaken between April 21 and 22, 2021. The survey was carried out online. The figures have been weighted and are representative of all U.S. adults (aged 18+).


About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Biomedtracker, Scrip, Pink Sheet and In Vivo to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.


With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isnt covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com


Informa Pharma Intelligence PR Contact
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com
(213) 318-4500


____________________________
1
New responses were added to comparative questions within the Q2 2021 survey that did not appear in the 2020 survey, including a none of these option.



Primary Logo

Copyright © 2022 - Todos os direitos reservados para o Grupo Estado.

As notícias e cotações deste site possuem delay de 15 minutos.
Termos de uso
Siga nossas redes: